Background. Superinfection with hepatitis D virus (HDV) may increase the risk for hepatitis flares and chronic hepatic complications in patients with chronic hepatitis B virus (HBV) infection. This retrospective observational study aimed to examine the incidence of and factors associated with recent HDV superinfection among individuals coinfected with human immunodeficiency virus (HIV) and HBV.
Hepatitis D virus (HDV) is a defective RNA virus that requires the presence of the hepatitis B virus (HBV) surface antigen (HBsAg) to infect the hepatocytes [1] . The prevalence of HDV infection varies widely with different geographic regions studied [2, 3] , depending on the prevalence of HBV infection in the general population and the risk factors for HBV transmission. It has been estimated that approximately 5% of HBV carriers are coinfected with HDV, leading to an estimate of 15 million persons infected with HDV worldwide [2, 3] .
The majority of HDV infections are acquired through parenteral and sexual routes [2, 3] , both of which are also important routes for human immunodeficiency virus (HIV) transmission. Compared with patients who are at risk for sexually transmitted infections, patients who are injection drug users (IDUs) have a significantly higher prevalence of HDV infection, suggesting that HDV is more efficiently transmitted by injections of contaminated blood or diluent than by sexual intercourse [4] . HDV infection has been considered to be the most severe form of viral hepatitis [2, 5, 6] , and treatment options for HDV infection are limited [2, 7] . HDV coinfection increases the risk for hepatitis flares and chronic hepatic complications [2] ; furthermore, patients with HBV/HDV coinfection have a significantly increased risk for hepatocellular carcinoma compared with patients with HBV monoinfection and the general population [8] .
HDV infection can occur simultaneously with acute HBV infection in patients without preexisting HBV infection (coinfection), or HDV infection may occur in those patients with chronic HBV infection (superinfection) [2, 5, 6] . Superinfection with HDV in patients with chronic HBV infection is more likely to cause chronic HDV infection, which may lead to episodes of hepatitis exacerbations, rapid progression of chronic liver disease, hepatic failure, and deaths.
With the advent of combination antiretroviral therapy (cART) in 1996, the survival of HIV-infected patients has significantly improved, and many HIV/HBV-coinfected patients now live on to develop the late complications (including death) related to chronic hepatotropic virus infections [9] . Notably, among such hepatotropic viruses is hepatitis C virus (HCV), which is increasingly reported among men who have sex with men (MSM) in many developed countries because of the shared routes of transmission for HIV and HCV [10, 11] . However whether the same is true for HDV remains largely unknown, as HDV is less well studied. In this study, we aimed to investigate the incidence of and factors associated with recent HDV infection among HIV/HBV-coinfected patients in Taiwan, where the prevalence of chronic HBV infection is estimated to be 18%-20% among adults who were born before implementation of the nationwide HBV vaccination program in 1984 [12] .
MATERIALS AND METHODS

Study Setting and Population
The retrospective cohort study was conducted at the National Taiwan University Hospital in Taiwan between 1992 and 2012. The cART that was introduced in 1997 was provided according to the national HIV treatment guidelines. Tenofovir was not available as the first-line agent until mid-2011. Although entecavir and adefovir were available in clinical use, HIV-infected patients who were already on lamivudinecontaining cART rarely received entecavir or interferon simultaneously for chronic HBV infection. Monitoring of CD4 lymphocyte count, plasma HIV RNA load, and biochemistry was performed every 3-6 months within the first year of initiation of cART and every 6 months and on an as-needed basis thereafter.
HIV/HBV-coinfected patients who were aged ≥18 years, and had 2 or more follow-up visits at the hospital with an interval >3 months were enrolled for assessment of HDV seroepidemiology. The present study included all HIV/HBV-coinfected patients with negative anti-HDV immunoglobulin G (IgG) at baseline who had at least 1 subsequent follow-up of HBV DNA load to assess the virologic response to lamivudine with or without tenofovir. Anti-HDV antibody testing was performed in the last available blood samples, and all of the archived blood samples of the patients who tested positive for anti-HDV IgG were tested retrospectively to estimate the timing and incidence of recent HDV seroconversion. A standardized case record form was used to collect information on demographics; serologies of HBV, HCV, and syphilis; cART; aminotransferase levels; CD4 count; and plasma HIV RNA load. The research ethics committee of the hospital approved the study and the patients gave written informed consent (registration number 200705072M). 
Nested Case-Control Study
To better understand the factors associated with HDV seroconversion, a nested case-control study with 2 controls for each case was conducted. The case patients were recent HDV seroconverters, whereas the control patients were those who had similar follow-up duration to the case patients but without HDV seroconversion throughout the follow-up period. Cases and controls were further matched for age (±5 years), sex, risk for HIV transmission, baseline CD4 count (±20 cells/µL), and plasma HIV RNA load (±0.5 log 10 copies/mL). Because our cohort consisted of a small proportion of IDUs and only 1 of 34 IDUs seroconverted for HDV during the observation period (data not shown), we excluded IDUs from the case-control study.
Definitions
Recent HDV seroconversion was defined as the first positive anti-HDV antibody detected within 1 year of the last negative anti-HDV. The date of HDV seroconversion was arbitrarily assigned as the midpoint between the date of the last negative and that of the first positive anti-HDV result. The overall incidence rate of HDV seroconversion in 1992-2012 was estimated, and 3 study periods were defined to assess the trends of recent HDV infection: 1992-2001, 2002-2006, and 2007-2012 . Within the 6 months of HDV seroconversion or within the 6 months of the last anti-HDV testing, patients with new rapid plasma reagin (RPR) seroreactivity or a 4-fold increase in RPR titers were diagnosed as having recent syphilis. The end date of the study was the last date the patients had follow-up visits at the hospital, death, or 31 December 2012, whichever occurred first.
Combination ART was defined as the combination of at least 3 antiretroviral agents that contained 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus protease inhibitor, 1 non-NRTI, or integrase inhibitor; or 3 NRTIs. . HDV load was determined using SYBR green realtime polymerase chain reaction (PCR) assay with a lower detection limit of 80 copies/mL. The primer pairs used were HDV-856 (5′-AGG TGG AGA TGC CAT GCC GAC-3′) and HDV-1275 (5′-GGA YCA CCG AAG AAG GAA GGC C-3′). For phylogenetic analysis, HDV delta-gene fragments (nt 856-1275 relative to HDV reference strain JA-M27) were PCR amplified and sequenced using an automatic sequencer (3100 Avent Genetic Analyzer, ABI). GenBank accession numbers for sequences derived in this study were KF678406 through KF678433, wherein KF678406 to KF678417 were the sequences for HDV identified from the HDV seroconverters. Sequences were aligned with Clustal W listed in the MEGA (molecular evolutionary genetics analysis) analytical package (version 3.0) with minor manual adjustments. The phylogenetic trees were constructed by the neighbor-joining method based on the Kimura 2-parameter distance matrix listed in the MEGA software. Bootstrap values >700 of 1000 replicates were considered significant.
Statistical Analysis
All statistical analyses were performed using SPSS software version 16.0 (SPSS Inc, Chicago, Illinois). Categorical variables were compared using χ 2 or Fisher exact test and noncategorical variables were compared using Student t test or Mann-Whitney U test. All tests were 2-tailed and a P value <.05 was considered to be statistically significant. The incidence rate of HDV seroconversion in each study period was calculated as the number of HDV seroconversion per 1000 person-years of follow-up (PYFU). Poisson regression was used to compare incidence rates of HDV seroconversion among the 3 study periods (1992-2001, 2002-2006, and 2007-2012) .
RESULTS
HDV Seroincidence in the 3 Study Periods
During the 20-year study period, 516 HIV/HBV-coinfected patients sought HIV care at the hospital and 375 patients (72.7%) with at least 2 blood samples for quantification of plasma HBV load were enrolled for determinations of anti-HDV IgG. The study flow is shown in Figure 1 . Compared with patients who were excluded from analysis, those included were more likely to be male (96.8% vs 92.9%, P = .05) and MSM (72.5% vs 50.4%, P < .0001) (data not shown). Overall, HDV seropositivity was noted in 38 of 375 (10.1%) HIV/HBV-coinfected patients ( 
Case-Control Study
For the 15 case patients who had recent HDV seroconversion and were not IDUs, 30 matched controls were identified. The clinical characteristics of the case and control patients are shown in Table 2 . At baseline, case and control patients had similar CD4 count, plasma HIV RNA and HBV loads, HCV seropositivity, and cART containing lamivudine and/or tenofovir. However, compared with controls, case patients were significantly more likely to have elevated levels of total bilirubin and aminotransferases and RPR titers ≥1:32 (26.7% vs 3.3%; Table 2 ). Recent syphilis was more common in case patients than in controls (23.1% vs 11.5%, P = .346), although statistical significance was not reached because of small case numbers.
HDV Virology
Of the 38 patients who were seropositive for HDV at baseline ( prevalent HDV infection) or during follow-up (incident The case patients and controls were matched for age (±5 years), sex, risk for HIV transmission, baseline CD4 count (±20 cells/µL), and plasma HIV RNA load (±0.5 log 10 copies/mL). (Figure 3 ). The genotypes remained unchanged in the blood samples collected sequentially from those 12 patients with HDV seroconversion (data not shown). In the phylogenetic analysis of all HDV strains from HIV-infected or HIV-uninfected IDUs in our previous study (Supplementary Figure 1) [13] and from HIVinfected patients with prevalent and incident HDV infections who were not IDUs in this study (Figure 3 ), we did not identify clusters of HDV sequences.
Plasma HBV Viral Load and HBsAg Titers
The sequential changes of plasma HIV, HBV, and HDV loads and HBsAg titers of the HDV seroconverters before and after HDV seroconversion are shown in Figure 4 . Among the 16 seroconverters, 3 were excluded from analysis: 1 who died within 6 months of HDV seroconversion; 1 IDU who did not receive cART during the study period; and 1 who received cART after HDV seroconversion. All the remaining 13 patients had been diagnosed with HIV/HBV coinfection and were given cART containing lamivudine at enrollment. Before HDV seroconversion, a significant decline of median plasma HBV DNA load from 6.84 to 1.85 log 10 copies/mL (P = .009) and a significant but a less dramatic decline of HBsAg titers from 3.16 to 2.54 log 10 IU/mL (P = .013) were observed in patients following initiation of cART. HDV seroconversions occurred 0.5-4 years after initiation of cART. No significant changes of plasma HIV, HBV, and HDV loads and HBsAg titers in the HDV seroconverters were observed between the last seronegative and the first seropositive time points. The median plasma HBV and HDV load and HBsAg titer when HDV seroconversion was detected was 1.71 log 10 copies/mL (range, 1.71-3.66 log 10 copies/ mL), 3.21 log 10 copies/mL (range, 2.76-4.64 log 10 copies/mL), and 2.39 log 10 IU/mL (range, 1.71-2.94 log 10 IU/mL), respectively ( Figure 4 ). One year after HDV seroconversion, a decrease of plasma HDV load (median, 3.01 log 10 copies/mL; P = .81) and an increase of HBsAg titer (2.74 log 10 IU/mL; P = .22) were observed in the patients, whereas the plasma HBV loads remained stably suppressed (1.71 log 10 copies/mL; P = .05).
DISCUSSION
In this longitudinal follow-up study conducted in a country that used to be hyperendemic for chronic HBV infection [12, 14] , we found that the incidence rate of recent HDV infection among HIV/HBV-coinfected patients who were not IDUs increased between 1992 and 2012; furthermore, HDV seroconversion among these patients was associated with hepatitis flares and recent syphilis. The prevalence of HBV infection has been on the decrease in the developed world where HBV vaccination programs are implemented [15, 16] . However, HDV seroprevalence has not shown a similar decline in these developed countries, which may be related to ongoing risk behaviors that facilitate HDV transmission among persons at risk and immigration of persons from regions endemic for HBV and HDV infections [17, 18] . In Taiwan, the prevalence of chronic HBV infection remains in the range of 15%-20% among adults who were born before the implementation of the nationwide neonatal HBV vaccination program in 1984 [12, 14] . Despite the high prevalence of chronic HBV infection, HDV seroprevalence was 9.3% and 2.3% in HIV-infected and HIV-uninfected patients who were not IDUs, respectively, in our previous survey [13] , which is similar to the rates reported in developed countries with much lower HBV seroprevalence [19] .
Similar to HCV, HDV can be acquired through sexual routes [20] [21] [22] [23] . The findings of the increasing trends of HDV seroconversion and the association of HDV seroconversion with syphilis in this study echo the concurrent finding of recent HCV infections in Taiwan and many other developed countries [10, 11] . In Taiwan, the incidence of recent HCV seroconversion (overall incidence rate of 7. [11] . The association between the increasing trends of recent syphilis and both trends of HCV and HDV seroconversion suggests that HDV or HCV transmission may be facilitated by syphilis that may present with ulceration in cases of primary or secondary syphilis, or that syphilis is a surrogate marker for risky sexual behaviors that may increase HDV or HCV transmission.
Long-term treatment with potent anti-HBV therapy such as entecavir and tenofovir can maintain prolonged suppression of HBV replication, which has been shown to result in regression of cirrhosis of the liver and reduction of liver-related and allcause mortality in HIV-uninfected patients [24, 25] . Therapeutic options for HDV infection are limited, however, and current potent anti-HBV agents such as entecavir with or without interferon fail to eradicate HDV [26, 27] . Despite long-term suppression of HBV replication using potent nucleoside/nucleotide analogues, HBsAg titers decay very gradually, so much so that the probability of HBsAg clearance is remote during the patient's lifetime [28] , thus providing a wide window of opportunity for HDV superinfection, as demonstrated in our study.
The findings of our study are important in terms of longterm successful management of HIV-infected patients in the era of cART containing tenofovir when AIDS-related morbidity and mortality have significantly declined [29] , A recent study from Japan demonstrated that use of tenofovir with or without lamivudine significantly decreased the risk for HBV acquisition by 90% [30] ; however, complacency with the effectiveness of cART containing tenofovir or lamivudine with resultant inconsistent adoption of safe sex practices may allow breakthrough of HBV, HCV, and other sexually transmitted infections to occur, which may pave the way for HDV coinfection or superinfection [31] . Moreover, in HIV/HBV-coinfected patients with hepatitis flares or possibly even new syphilis, it is important to consider anti-HDV antibody and HDV RNA testing in high-risk patient populations.
The strengths of the study are the relatively large number of HIV/HBV-coinfected patients in a country with easy access to HIV and HBV care and the concomitant detection of plasma HBV and HDV loads, and HBsAg levels of sequentially collected blood samples to examine dynamic trends while patients are on cART. However, there are also several limitations to our study. First, the case number of HDV seroconversion remains small, which makes the identification of significant associated factors and clusters of recent HDV infections challenging. Second, we may have underestimated or overestimated the HDV seroincidence because not all HIV/HBV-coinfected patients had sequential blood samples for anti-HDV antibody testing. Third, we were not able to estimate the timing of HDV seroconversion precisely because blood sampling was performed at 3-to 6-month intervals when the patients returned for monitoring of plasma HIV RNA loads and CD4 counts. Fourth, although we identified the association between HDV seroconversion and higher RPR titers, we did not have information on sexual behaviors, a history of bleeding or injury during the sexual encounters, or substance abuse, which may preclude identification of the behaviors that facilitate HDV transmission. Fifth, 4 patients had HDV viremia when they were seronegative for anti-HDV antibody (Figure 4) , and the HDV seroconversion occurred 1-8 months after HDV viremia. Therefore, the delayed seroconversion might lead to our underestimation of HDV incidence, although this did not affect the trend of increasing HDV incidence in the 3 study periods. Last, the numbers of IDUs (who used to have the highest HDV seroprevalence) and heterosexuals are small in our study, which may limit the generalizability of our findings.
In conclusion, the overall seroincidence of recent HDV infections in HIV/HBV-coinfected patients was 9.07 per 1000 PYFU in Taiwan, which increased significantly from 1992-2001 to 2007-2011. Recent HDV seroconversion was associated with hepatitis flares and syphilis despite the use of cART containing lamivudine or tenofovir. Vigilance should be maintained against acquisition of sexually transmitted infections that include hepatotropic viruses in the cART era.
